SCHEMBL343728

SCHEMBL343728

CCOC(=O)c1ccc(-c2c(N)c(C#N)c3ccccn23)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
ALDH1A1 P00352 6/20 0.45
MAPK1 P28482 3/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
KDM4E B2RXH2 7/20 0.43
CYP1A2 P05177 3/20 0.43
CYP3A4 P08684 2/20 0.43
IDO1 P14902 1/20 0.43
HBB P68871 1/20 0.43
HIF1A Q16665 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL343004 0.83 ALDH1A1 (0.52) ALDH1A1KMT2AMEN1L3MBTL1KDM4E
SCHEMBL4910987 0.78 SMN1; SMN2 (0.61) ALDH1A1MAPK1KMT2AMEN1POLB
SCHEMBL344160 0.74 ALDH1A1 (0.41) ALDH1A1MAPK1KMT2AMEN1L3MBTL1
SCHEMBL9619432 0.72 ALDH1A1 (0.56) ALDH1A1MAPK1KMT2AMEN1POLB
SCHEMBL17331394 0.71 IDO1 (0.51) ALDH1A1MAPK1KMT2AMEN1POLB
SCHEMBL17331499 0.70 ALDH1A1 (0.48) ALDH1A1MAPK1KMT2AMEN1POLB
SCHEMBL9806456 0.70 SMN1; SMN2 (0.47) ALDH1A1MAPK1KMT2AMEN1POLB
SCHEMBL9619336 0.70 ALDH1A1 (0.49) ALDH1A1MAPK1KMT2AMEN1POLB
SCHEMBL5737978 0.70 KMT2A (0.63) ALDH1A1KMT2AMEN1POLBKDM4E
SCHEMBL7125525 0.70 ALDH1A1 (0.59) ALDH1A1MAPK1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748452-B2 Indolizine derivative and use thereof for medical purposes KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-06-10 US disclosed
EP-2415771-B1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL (JP) 2013-07-31 EP disclosed
EP-2415771-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES Kissei Pharmaceutical Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015972-A1 INDOLIZINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, INMT, PON1 PSEN1 4157/4885PSEN2 4361/4885APH1B 4572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.